All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
ECHELON-3 subgroup analysis: Brentuximab vedotin + lenalidomide + rituximab for older patients with R/R DLBCL
|
Despite recent treatment advances, there remains an unmet need for safe, effective, and durable therapies for patients with R/R DLBCL. Brentuximab vedotin (BV) is an anti-CD30 ADC with demonstrated efficacy and safety when combined with lenalidomide (Len) and rituximab (R) in heavily pretreated populations. The phase III ECHELON-3 trial (NCT04404283) investigated the efficacy and safety of BV+Len+R vs Pbo+Len+R in patients with R/R DLBCL who received ≥2 prior lines of systemic therapy. Results from a subgroup analysis of findings in older patients aged ≥65 years (n = 155) and ≥75 years (n = 86) were presented at the 66th ASH Annual Meeting and Exposition by Bartlett.1 |
| Key learnings |
| OS was improved with BV+Len+R vs Pbo+Len+R, at 15.9 months vs 8.5 months (p = 0.0043) in patients aged ≥65 years and 21.5 months vs 8.5 months (p = 0.0189) in patients aged ≥75 years. |
| PFS was longer with BV+Len+R vs Pbo+Len+R, at 5.7 months vs 2.8 months (p = 0.0003) in patients aged ≥65 years and 7.1 months vs 4.0 months (p = 0.0136) in patients aged ≥75 years. |
| ORR was higher with BV+Len+R vs Pbo+Len+R, at 70.9% vs 46.1% (p = 0.0020) in patients aged ≥65 years and 70.8% vs 52.6% (p = 0.1159) in patients aged ≥75 years. CR rates were 45.6% vs 19.7% and 45.8% vs 26.3% in patients aged ≥65 and ≥75 years, respectively. |
| The treatment was well-tolerated, with no clinically meaningful safety trends reported in any age group, suggesting that BV+Len+R could be a viable therapeutic option for the treatment of older patients with R/R DLBCL. |
Abbreviations: ADC, antibody–drug conjugate BV, brentuximab vedotin; CR, complete response; DLBCL, diffuse large B-cell lymphoma; Len, lenalidomide; OS, overall survival; ORR, overall response rate; Pbo, placebo; PFS, progression-free survival; R, rituximab; R/R, relapsed/refractory.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following do you consider a key challenge when implementing the BrECADD regimen for the treatment of Hodgkin lymphoma?
